Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pertuzumab biosimilar - CinnaGen

Next Previous
Drug Profile

Pertuzumab biosimilar - CinnaGen

Alternative Names: Pertuzumab

Latest Information Update: 05 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CinnaGen
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Dimerisation inhibitors; ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Breast cancer

Most Recent Events

  • 24 Mar 2021 Phase-III development is ongoing Breast cancer (Combination therapy, Neoadjuvant therapy, Late-stage disease) in Iran (IRCT20150303021315N11)
  • 27 May 2020 CinnaGen completes a phase III trial in Breast cancer in Iran (NCT04957212)
  • 04 Mar 2020 CinnaGen completes a phase III trial in Breast cancer (Combination therapy, Neoadjuvant therapy, Late-stage disease) in Iran, before March 2020 (IV) (IRCT20150303021315N11)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top